Cancer Moonshot℠ – Funding Opportunities
Following receipt of the Blue Ribbon Panel report, NCI identified funding opportunity announcements (FOAs) from within its extensive research portfolio that address the goals of the Cancer Moonshot. These opportunities mark the beginning of a growing Cancer Moonshot portfolio which will continue to expand given the authorization of the 21st Century Cures Act to fund the Beau Biden Cancer Moonshot with $1.8 billion over 7 years. While the FOAs listed below highlight research initiatives that align with the efforts of the Cancer Moonshot, they may be supported with existing funds or with the 21st Century Cures funding.
Planning for implementation of longer-term scientific initiatives is also underway. We have established implementation teams aligned with the BRP recommendations. The teams include NCI extramural and intramural scientists, and experts from several other NIH institutes and centers. Team members are considering multiple ways to fund the best science, including grants, supplements, and other mechanisms, and, where appropriate, to form partnerships with foundations, academia, and the private sector. We look forward to engaging our extramural colleagues in this process.
We will continue to update this page as new funding opportunities become available. Please check back often or sign up to receive automatic email updates for these announcements and other Cancer Moonshot-related activities.
|BRP Recommendation||Title||Announcement Number||Opening Date||Expiration Date|
|Cancer Immunotherapy Translational Science Network||Collaborative Research Projects to Enhance Applicability of Mammalian Models for Translational Research (Collaborative R01)||PAR-16-058||1/5/2016||5/8/2017|
|Cancer Immunotherapy Translational Science Network||Metabolic Reprogramming to Improve Immunotherapy (R01)||PAR-16-228||9/5/2016||9/8/2019|
|Cancer Immunotherapy Translational Science Network||Metabolic Reprogramming to Improve Immunotherapy (R21)||PAR-16-229||9/16/2016||9/8/2019|
|Cancer Immunotherapy Translational Science Network||Canine Immunotherapy Trials and Correlative Studies (U01)||RFA-CA-17-001||2/7/2017||3/8/2017|
|Cancer Immunotherapy Translational Science Network||Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24)||RFA-CA-17-002||2/7/2017||3/8/2017|
|Cancer Immunotherapy Translational Science Network||Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01)||RFA-CA-17-015||2/7/2017||3/8/2017|
|Cancer Immunotherapy Translational Science Network||Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24)||RFA-CA-17-016||2/7/2017||3/8/2017|
|Cancer Immunotherapy Translational Science Network||Cancer Immune Monitoring and Analysis Centers (CIMACs) (U24)||RFA-CA-17-005||2/17/2017||3/18/2017|
|Cancer Immunotherapy Translational Science Network||Cancer Immunologic Data Common (CIDC) (U24)||RFA-CA-17-006||2/17/2017||3/18/2017|
|Therapeutic Target Identification to Overcome Resistance||Mechanisms of Cancer Drug Resistance and Sensitivity (U54)||RFA-CA-17-009||2/3/2017||3/4/2017|
|National Cancer Data Ecosystem||PDX Development and Trial Centers (PDTCs) (U54)||RFA-CA-17-003||2/3/2017||3/4/2017|
|National Cancer Data Ecosystem||PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24)||RFA-CA-17-004||2/3/2017||3/4/2017|
|Fusion Oncoproteins in Childhood Cancers||Gene Fusions in Pediatric Sarcomas (R01)||PA-16-251||9/5/2016||5/8/2019|
|Fusion Oncoproteins in Childhood Cancers||Gene Fusions in Pediatric Sarcomas (R21)||PA-16-252||9/16/2016||5/8/2019|
|Fusion Oncoproteins in Childhood Cancers||Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp)||PA-17-138||3/1/2017||3/29/2018|
|Generation of Human Tumor Atlases||Emerging Questions in Cancer Systems Biology (U01)||PAR-16-131||5/24/2016||11/24/2018|
|New Enabling Technologies||Activities to Promote Technology Research Collaborations (APTRC) for Cancer Research (Admin Supp)||PA-17-143||3/12/2017||12/13/2017|